Cargando…
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives
Osteosarcoma (OS) is an aggressive osteoid-producing tumor of mesenchymal origin, which represents the most common primary bone malignancy. It is characterized by a complex and frequently uncertain etiology. The current standard care for high-grade OS treatment is neoadjuvant chemotherapy, followed...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874676/ https://www.ncbi.nlm.nih.gov/pubmed/29439419 http://dx.doi.org/10.3390/biomedicines6010019 |